What question did this study set out to answer?

This research aims to evaluate the safety and effectiveness of the PRISMALUNG+ device for treating hypercapnia in moderate ARDS patients during ULPV.

March 26, 2026

305: Prospective Clinical Evaluation of New Ecco2r Technology With Ulpv in Moderate Ards Patients

Key Points

This research aims to evaluate the safety and effectiveness of the PRISMALUNG+ device for treating hypercapnia in moderate ARDS patients during ULPV.
Conducted a multicenter, prospective study in France from April 2021 to December 2023.
Included 58 moderate ARDS patients across 10 centers who received heparin and underwent tidal volume reduction.
Initiated sweep gas when PaCO2 >50 mmHg and monitored outcomes at 8 and 24 hours.
Tidal volume decreased from 6.0 to 4.0 mL/kg (p < 0.0001).
Driving pressure improved from 12.0 to 10.0 cmH2O (p=0.0001).
Respiratory acidosis resolved within 24 hours, with baseline pH unchanged and PaCO2 significantly reduced after treatment.

Abstract

Introduction: This multicenter, prospective, study in France evaluated the safety and effectiveness of PRISMALUNG+ (PL+), a new ECCO2R membrane lung designed for use alone or with continuous renal replacement therapy (CRRT safety was monitored until discharge or day 28. Results: Data are presented as median IQR, unless stated otherwise. Among 58 (PL+=42 patients; CRRT p = 0.2704) while baseline PaCO2 was 42.0 39.0-46.0 mmHg compared to 45.2 41.0-50.1 mmHg at 24 hours (p=0.0025). CO2 clearance after 8h was 82.3 mL/min (PL+) and 77.3 mL/min (CRRT however, 2 patients experienced minor ischemic strokes post-treatment, unrelated to the device. Conclusions: PL+ effectively and safely clears CO2 and enables ULPV without causing hypercapnic acidosis.

Perguntar à IA

Bookmark